Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics
Hakim Ben Abdallah,Claus Johansen,Lars Iversen
DOI: https://doi.org/10.2147/PTT.S294173
2021-06-29
Psoriasis: Targets and Therapy
Abstract:Hakim Ben Abdallah, Claus Johansen, Lars Iversen Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark Correspondence: Lars Iversen Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 45, Aarhus N, 8200, Danmark Tel +4578461848 Email Psoriasis is a common chronic inflammatory skin disease associated with several comorbidities and reduced quality of life. In the past decades, highly effective targeted therapies have led to breakthroughs in the management of psoriasis, providing important insights into the pathogenesis. This article reviews the current concepts of the pathophysiological pathways and the recent progress in antipsoriatic therapeutics, highlighting key targets, signaling pathways and clinical effects in psoriasis. Keywords: psoriasis, small molecules, signaling pathways, novel treatments, biologics Psoriasis is a common chronic inflammatory skin disease with regional prevalence varying between 0.14% and 1.99%. 1 Psoriasis vulgaris is the most common type seen in approximately 90% of psoriasis cases. It is characterized by erythematous and scaly lesions that may affect any site of skin, but commonly affects predilection sites (extensor surfaces and scalp). 2 , 3 Other less common types of psoriasis include: guttate psoriasis; inverse psoriasis; pustular psoriasis which may be generalized (generalized pustular psoriasis) or limited to palms and soles (palmoplantar pustulosis); and erythrodermic psoriasis, a rare, serious and widespread redness of the skin. 3 Psoriasis is associated with comorbidities (eg, psoriatic arthritis, cardiovascular events, inflammatory bowel disease), psychiatric disorders (depression, anxiety, suicidal ideation) and significantly reduced quality of life. 4 , 5 Genetic, environmental (eg, skin trauma, infections) and behavioral factors (eg, smoking) contribute to the development of psoriasis. 6 , 7 The pathogenesis of psoriasis is not fully elucidated yet, but most accepted concepts suggest an initiation and a maintenance phase of inflammation driven by an interplay between immune cells and keratinocytes mediated by cytokines. 8 , 9 The mainstay of treatment is immunosuppression including phototherapy, topical and systemic treatment. 2 In recent decades, the introduction of targeted therapy with biologics has led to major advancements in the management of psoriasis and further enhanced our understanding of the pathogenesis. This review provides the recent progress and insights from antipsoriatic therapeutics, highlighting key targets, signaling pathways and clinical effects in psoriasis vulgaris. Psoriasis is a T cell mediated disease dependent on cross-talk between the innate and adaptive immune systems, in which dendritic cells (DCs) and keratinocytes have key roles. 10 The psoriatic inflammation is characterized by an initiation phase, followed by chronic inflammation that is sustained by positive feedback loops. The exact immune events triggering the inflammatory cascade remain elusive. Autoantigens have been proposed as the pathomechanism of initiation. The most studied autoantigen is cathelicidin antimicrobial peptide, also known as LL-37, which is produced by immune cells and keratinocytes in response to skin injury ( Figure 1 ). 11 , 12 LL-37 forms complexes with self-DNA or RNA that activates plasmacytoid DCs (pDCs) through Toll-like receptor-9 (TLR-9) and TLR-7, respectively. 13 , 14 Subsequently, the pDCs produce interferon (IFN)-α that activates conventional DCs (cDCs). Moreover, RNA-LL37 may directly activate cDCs through TLR8. 14 Hereafter, activated cDCs stimulate and promote the expansion of autoreactive T cells through antigen presentation and secretion of cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)–12 and IL-23. 15 The differentiation of naive T cells to T helper 17 cells (Th17) depends on the secretion of IL-23 together with TGFβ and IL-6, whereas the differentiation to Th1 depends on IL-12. 15 , 16 The activated Th cells secrete cytokines; Th17 cells secrete IL-17, IL-22 and TNF-α, while Th1 cells secrete IFN-γ and TNF-α. These cytokines together stimulate the keratinocytes to proliferate and produce inflammatory cytokines (eg, IL-1, IL-6, TNF-α), chemokines (eg, CXCL1, CXCL2, -Abstract Truncated-